Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI

Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com


LAUSANNE, Switzerland, November 22, 2017 /PRNewswire/ --

The website provides patients with helpful information on the company's clinical trials 

Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website patients.debiopharm.com. The website provides patients and their caregivers with helpful information on Debiopharm's clinical trials and studies. It also offers accessible information about the clinical trial process in general.

     (Photo: http://mma.prnewswire.com/media/608971/Debiopharm_International_Website.jpg )

Debiopharm's main therapeutic areas are oncology and infectious diseases. The company is currently conducting trials in multiple indications like Ovarian cancer, Head & Neck cancer and
Non-Hodgkin Lymphoma. Additional studies are running in patients with Advanced Solid Malignancies as well. The website contains useful information for each clinical trial such as a short description of the trial process and its purpose, main inclusion criteria, as well as a map locating the study sites (in accordance with the information contained in the EU Clinical Trials Register and the clinicaltrials.gov website). The patient can print the information to discuss with his/her doctor.

"This website is intended to be a helpful tool for patients and their families", explains Christian Aeschlimann, Director of Clinical Operations at Debiopharm International SA. "They can find accessible information related to our clinical trials and treatment options. The website also allows users to share links of patient associations".

The website was developed in collaboration with the Superhuit agency in Lausanne. Created with the user experience in mind, the website includes intuitive design features to help patients to navigate easily and find information.

About Debiopharm International SA 

Part of Debiopharm Grouptm - a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews


Debiopharm International SA Contact
Christelle von Büren
Communication Coordinator
[email protected]
Tel: +41(0)21-321-01-11


These press releases may also interest you

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024...

at 07:27
Within just three months of its official launch, Blazesoft's Sportzino.com has secured its position as a dominant force in the U.S.social sports and gaming entertainment industry. The founders of Sportzino.com are...

at 07:25
AdaptiveX, a distinguished educational consulting and software firm, proudly announces its recent awards with the State of Delaware and Detroit Public Schools, marking significant progress in the field of educational equity and culturally responsive...

at 07:24
Ericsson today announced that on March 28, 2024, the independent compliance Monitor appointed by the U.S. Department of Justice (DOJ) (in June of 2020 in connection with Ericsson's resolution of historical violations of the Foreign Corrupt Practices...

at 07:20
EDITEDtm, the leading global retail intelligence platform, is excited to release the findings from its Customer-Centricity Index Self Assessment ? a first-of-its-kind benchmarking tool designed to help retailers audit their customer-centricity...

at 07:15
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") , InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise...



News published on and distributed by: